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NONINDOLIC MELATONIN-RECEPTOR AGENTS 
CHAPTER 4 
INTRODUCTION PART I1 
4.1 MELATONIN: A MAMMALIAN PINEAL AND RETINAL HORMONE 
At the end of the 1950's Lerner and co-workers, searching for a neurogenic factor 
responsible for depigmentation in vitiligo, became interested in the amphibian skin- 
lightening effect of pineal extracts, as already described by McCord and Allen in 1917 
[I]. In 1958 Lerner and co-workers succeeded in isolating, from thousands of bovine 
pineal glands, the compound responsible for this effect. This compound was identified 
by them as N-acetyl-5-methoxyt~yptamine and was named melatonin (ML, see Chart 
4.1) due to its ability to induce aggregation of melanin granules in amphibian 
melanophores [2-41. Since its first isolation, melatonin has been the subject of much 
investigation and, consequently, our knowledge about melatonin and the pineal gland, 
the major site of melatonin production, has increased considerably (for reviews, see ref. 
5-10). 
Nowadays, there is no longer any doubt that melatonin, the main hormone of the 
pineal gland, is a widely acting hormone that exerts a major impact not only on the 
function of the neuroendocrine-reproductive system, but also on the physiology of a 
variety of other endocrine and nonendocrine systems. In this respect, the conclusion that 
"melatonin is a hormone that goes where it wants to go and does what it wants to do" 
may not be an exaggeration [lo]. Nevertheless, only 30 years ago the mammalian pineal 
gland (gfandula pinealzs or epiphysis cerebri), a small organ appended to the brain, but 
located outside the blood-brain barrier, was regarded as a vestigial remnant of the 
photosensory epiphyseal organ ("third eye") of lower vertebrates devoid of any 
significant function. Presently, however, the assumption that the pineal gland is "the 
regulator of the regulators" [lo, 1 11, 1. e. the master gland of the body, which exerts 
control over all endocrine glands and influences all other organ systems, may not be far 
beside the truth. 
4.1.2 BIOSYNTHESIS, ECRETION AND METABOLISM 
The biosynthesis of the hormone melatonin is more widespread than initially 
envisaged. It is now well established that in mammals the primary sites of melatonin 
production are the pinealocytes of the pineal gland and, most likely, the photoreceptor 
cells of the retinas (for reviews and references, see ref. 6,8-10,12-16). This is not 
surprising, since these two tissues exhibit many morphological and developmental 
similarities, consistent with the idea that the mammalian pineal gland evolved fiom a 
photoreceptive organ. In addition to these structures, the orbital Harderian gland and the 
extraorbital lacrimal glands are endowed with the necessary enzymes to produce 
melatonin and even portions of the gastro-intestinal tract and certain blood cells are 
probably capable of synthesizing this hormone. Although apparently produced at 
several sites, plasma melatonin levels in mammals are derived essentially, if not 
exclusively, fi-om the pineal gland, as can be deduced fiom pinealectomy studies. 
Hence, retinal melatonin in mammals functions most likely as a local hormone. 
The biosynthesis of pineal melatonin is initiated by the active carrier-mediated 
uptake of the essential amino acid L-tryptophan (L-TRP) fiom the blood circulation. 
Subsequently a large fkaction of the L-tryptophan taken up by the pinealocytes is 
converted via L-5-hydroxytryptophan (L-5-HTP) to serotonin (5-hydroxytryptamine, 5- 
HT) through the action of tryptophan hydroxylase and aromatic L-amino acid 
decarboxylase, as outlined in Chart 4.1. The pineal concentration of serotonin is very 
high - higher than in any other body tissue. The prevailing view is that pineal serotonin 
Chart 4.1 Biosynthesis of melatonin. Abbreviations: AAAD, aromatic L-amino acid decarboxylase; 
HIOMT, hydroxyindole 0-methyltransferase; 5-HT, 5-hydroxytryptamine (serotonin); L-5- 
HTP, L-5-hydroxytryptophan; L-TRP, L-tryptophan; ML, melatonin (N-acetyl-5-methoxy- 
tryptamine); NAS, N-acetylserotonin (N-acetyl-5-hydroxytryptamine); NAT, N-acetyl- 
transferase; TH, tryptophan hydroxylase. 
serves purely as a precursor of melatonin. However, based on recent work it has been 
speculated that serotonin, released from pinealocytes under the influence of 
noradrenaline, may act on serotonin receptors on other pinealocytes and may modulate 
the adrenergic regulation of the biosynthesis of melatonin (see 4.1.3). A daily serotonin 
rhythm in the pineal gland has been documented in several mammalian species. The 
rhythm in pineal serotonin levels probably reflects its cyclic conversion to melatonin. 
Pineal serotonin levels are always highest during the light phase and decrease after 
darkness onset coincident with the rise in the nocturnal production of pineal melatonin, 
as described below. 
Whereas serotonin in the pineal gland is acted upon by several enzymes, the 
melatonin synthetic pathway is of major importance. The conversion of serotonin to 
melatonin involves two enzymatic steps, as outlined in Chart 4.1. The first step, which 
is the rate-limiting one, is the N-acetylation by a relatively specific pineal arylalkyl- 
amine N-acetyltransferase, also known as serotonin N-acetyltransferase, to yield N- 
acetylserotonin (N-acetyl-5-hydroxytryptamine, NAS). This acetyl group is provided by 
the cofactor acetyl coenzyme A. Subsequently, a methyl group is transferred from S- 
adenosylmethionine to N-acetylserotonin to yield melatonin; this reaction is catalyzed 
by the pineal enzyme hydroxyindole 0-methyltransferase. Both these enzymes are also 
responsible for the conversion of retinal serotonin to retinal melatonin. Although, in the 
retinas they are present in a much lower concentration. 
The rat was the first species in which it was shown that pineal N-acetyltransferase 
activity exhibits a rhythm that is circadian in nature*; it persists in constant darkness 
and can be suppressed by constant light (see 4.1.3). In the rat the nocturnal rise in the 
activity of this enzyme is extremely pronounced (20- to 100-fold increase at night) and 
contributes very likely significantly to the increased production of melatonin during 
darkness under normal conditions. Most studies on hydroxyindole 0-methyltransferase 
have shown high pineal activity of this enzyme, which does not exhibit a rhythrmc 
variation. Consequently, at night when pineal N-acetylserotonin levels are elevated this 
compound is rapidly converted to melatonin. By analogy to the activities of the pineal 
enzymes, retinal N-acetyltransferase activity shows a nocturnal rise, while retinal 
hydroxyindole 0-methyltransferase activity displays no circadian rhythm. 
The nocturnal rise in pineal melatonin levels is, depending on the mammalian 
species, usually in the order of 2- to 12-fold. Analogously, daily oscillations in retinal 
melatonin levels with highest values at night have been reported. Due to its almost 
exclusive nocturnal synthesis, melatonin has become to be known as the "chemical 
expression of darkness" and as the "Dracula of the endocrine system" [17,18]. The 
nocturnal production of pineal melatonin is unrelated to the circadian cycle of 
locomotor activity which a mammalian species displays. Thus, regardless of whether 
animals are diurnally active, nocturnally active, or if they display a crepuscular activity 
* A circadian rhythm is a rhythm with a period length close to 24 h that persists, or "free-runs", under 
constant conditions. 
pattern, the pineal gland produces the majority of its melatonin at night. Furthermore, 
the duration of elevated pineal melatonin levels is roughly proportional to the duration 
of the daily dark period. Considering that under natural conditions the light-to-dark 
ratio, i.e. the photoperiod, changes on a daily basis, the melatonin message that the 
pineal gland sends to an organism also varies daily and, obviously, seasonally. In fact, 
melatonin is an important conveyer of photoperiodic information to an organism and 
can be considered as a time-giving hormone, which provides information concerning 
both the time of day and the time of year to every organ in the body (see 4.2). 
Unlike many other hormones, pineal melatonin seems not to be stored for secretion 
upon demand; rather, it is enzymatically produced upon demand and it escapes rapidly 
into the systemic circulation. The general consensus is that due to its high lipophilicity, 
melatonin simply diffuses out of the pinealocytes into the rich capillary network that 
pervades the pineal gland en route to its targets. However, as with many other 
hormones, blood melatonin levels suggest a pulsatile manner of secretion, tacitly 
implying some form of active secretion of pineal melatonin. Also due to its high 
lipophilicity, every cell of the body is exposed to melatonin very soon after its diffusion 
from the pinealocytes into the blood circulation. Thus, if the cell has the capacity of 
"reading" the melatonin message, i.e. possesses specific receptors for melatonin (see 
4.4), it can respond quickly to changes in circulating melatonin levels. If a particular 
cell can not read the melatonin message, it may respond to a signal, e.g. a hormone, 
provided by a melatonin-responsive organ. 
The majority of circulating melatonin, essentially from pineal origin, is bound to 
plasma albumin. In humans and rodents approximately 90% of the melatonin is cleared 
during a single passage through the liver (melatonin has approximately a plasma half- 
life of 12 min in rats). Hepatic cells convert most of the melatonin to 6-hydroxy- 
melatonin (Chart 4.2); this compound is subsequently sulfated (70%), yielding 6- 
sulfatoxymelatonin, or glucuronidated (5%). In the brain, melatonin is metabolized via 
ring-opening to N-acetyl-5-methoxykynwenamine (12%) (Chart 4.2). Other minor 
metabolites of melatonin are produced in various organs. Among these minor 
metabolites are N-acetylserotonin conjugates, 5-methoxy-indoleacetic acid and a cyclic 
isomer of 2-hydroxymelatonin. Less than 1% of circulating melatonin escapes 
metabolism. All metabolites are excreted into the urine and, as with circulating 
melatonin concentrations, the nocturnal excretion rates of these constituents are hlgher 
than those during dayhme. Recent studies show that retinas, unlike the pineal gland, 
have the capacity for rapid metabolism of melatonin. Thus, retinal melatonin can 
undergo a local multistep degradation, ultimately leading to 5-methoxytryptophol (5- 
MTol) and 5-methoxyindoleacetic acid (5-MIAA) (Chart 4.2). Thls rapid retinal 
metabolism may provide an explanation for the very small contribution of melatonin of 
retinal origin to circulating melatonin levels. 
Chart 4.2 Metabolism of melatonin. Abbreviations: 6-HML, 6-hydroxymelatonin; 5-MIAA, 5- 
methoxyindoleacetic acid; ML, melatonin; 5-MT, 5-methoxytryptamine; 5-MTol, 5-  
methoxytryptophol; N-Ac-5-MKA, N-acetyl-5-methoxykynurenamine; N-Ac-N-Fo-5-MKA, 
N-acetyl-N-fomyld-methoxykynurenamine. 
Nowadays, it is well established for mammals, including man, that the rhythrmc 
production of pineal melatonin with its maximum occuring during darkness is strongly 
endogenous, i.e. it persists in constant darkness, and is actually generated by one or 
more self-sustaining biological circadian clocks in the hypothalamic suprachiasmatic 
nuclei (SCN) (for reviews, see ref. 6-9). The SCN are the major, if not the sole, 
circadian pacemakers in mammals; their destruction abolishes not only the circadian 
rhythm in pineal melatonin production, but also a variety of other circadian rhythms. 
The SCN are entrained precisely to the 24-hour period by the prevailing environmental 
photoperiodic conditions, i. e. the daily light-dark cycle. Beside this action as an external 
"Zeitgeber", light of suitable intensity and spectral composition has the ability to 
suppress directly pineal melatonin production during darkness. Light information from 
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Figure 4.1 Diagrammatic representation of the neuronal connections between the eyes and the pineal 
gland, believed to be similar in all mammals. Abbreviations: ICC, intermedlolateral cell 
column; PVN, paraventricular nuclei; SCG, superior cervical ganglion; SCN, supra- 
chiasmatic nuclei. 
the retinas, the only mammalian organs capable of transducing photic input into 
neuronal signals, is conveyed directly to the SCN by a special projection called the 
retinohypothalamic tract. Integration of the light information and the endogenous clock 
information takes place at the level of the SCN. The SCN communicate with the pineal 
gland via a complex multicomponent neuronal pathway, which was elucidated by a 
series of lesion experiments. This neuronal pathway, diagrammatically represented in 
Figure 4.1, includes a neuronal connection fkom the SCN to the paraventricular nuclei 
(PVN). Subsequently, neurons project fiom these hypothalamic nuclei via the medial 
forebrain bundle and the reticular formation to the intermediolateral cell column of the 
upper thoracic spinal cord. Preganglionic sympathetic neurons, originating from this 
part of the spinal cord, take care of the neuronal connection to the superior cervical 
ganglion (SCG). From this ganglion, postganglionic sympathetic neurons (newi conarii) 
course back to the brain and innervate the pineal gland, which acts as a neuroendocrine 
transducer, i.e. the neuronal input is converted into an endocrine output. In addition to 
this peripheral sympathetic innervation of the pineal gland, central innervation via the 
pineal stalk has been documented in some mammals. The physiological significance of 
this second pathway remains unknown. 
The nocturnal production of pineal melatonin is a result of the release of 
noradrenaline (NA) fiom the nerve endings of postganglionic sympathetic neurons. 
During the day, the SCN inhibit actively the release of noradrenaline from intrapineal 
sympathetic neurons. Conversely, at night, the inhibitory message from the SCN to the 
pineal gland is suppressed and the release of noradrenaline is disinhibited. Once 
released, noradrenaline interacts with P 1- and al-adrenergic receptors -at least in the 
rat and very likely also in man- located on the membranes of the pinealocytes (Figure 
4.2) (for reviews and references, see ref. 6-9,12). Stimulation of pinealocyte Pi- 
receptors, linked via a stimulatory guanine nucleotide-binding regulatory protein (Gs- 
protein) to. the enzyme adenylyl cyclase, induces an intracellular increase in cyclic 
adenosine 3',5'-monophosphate (CAMP) formation. This increase triggers the induction 
as well as the activation of N-acetyltransferase, the rate-limiting enzyme in the 
production of melatonin, and consequently, mediates the nocturnal increase in pineal 
melatonin production. The transcriptional and translational mechanisms intervening 
between the increased CAMP formation and the increased N-acetyltransferase activity 
are not well characterized. Although stimulation of pinealocyte al-receptors alone has 
no effect on cAMP formation, and thus on pineal melatonin production, the concurrent 
stimulation of pinealocyte al-receptors potentiates markedly the increase in CAMP 
formation resulting &om stimulation of pinealocyte Pi-receptors. The mechanism 
underlying this remarkable amplification appears to involve interactions or "cross-talk" 
between the cAMP and the diacylglyceroVinositol 1,4,5-triphosphate (DAG/IP3) 
transduction systems. Presumably, stimulation of al-receptors activates via a G-protein 
VIP NA NA 
Figure 4.2 Regulation of pineal melatonin production. Abbreviations: al, al-adrenergic receptor; P 1, 
Pi-adrenergic receptor; AC, adenylyl cyclase; ATP, adenosine triphosphate; CAMP, cyclic 
adenosine 3',5'-monophosphate; DAG, diacylglycerol; G(,), (stimulatory) guanine 
nucleotide-binding regulatory protein (G-protein); HIOMT, hydroxyindole O-methyl- 
transferase; 5-HT, serotonin; IP3, inositol 1,4,5-triphosphate; ML, melatonin; NA, 
noradrenaline; NAS, N-acetylserotonin; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, 
protein kinase C; PLC, phospholipase C; SNAT, serotonin N-acetyltransferase; VIP, 
vasoactive intestinal peptide (receptor). 
the enzyme phospholipase C and mediates by the opening of a ligand-dependent 
channel the influx of calcium, generating the second messengers DAG, IP3 and 
calcium. DAG and calcium trigger very likely in a synergistic manner the translocation 
of protein kinase C from the cytosol to the plasma membrane and its subsequent 
activation. Protein kinase C activation results ultimately in an enhanced Pi-receptor- 
stimulated CAMP formation, probably by phosphorylating the enzyme adenylyl cyclase 
itself or the Gs-protein, which couples it to the P 1-receptors. 
In addition to noradrenaline, it has been shown that vasoactive intestinal peptide 
(VIP), present in nerve terminals in the pineal gland, through the interaction with 
pinealocyte VIP receptors, induces a rapid increase in pinealocyte CAMP formation, N- 
acetyltransferase activity and melatonin production (Figure 4.2). The VIP receptors are 
linked via Gs-proteins to the enzyme adenylyl cyclase. VIP-mediated effects are also 
amplified by al-receptor stimulation, apparently by the same protein kinase C 
mechanism. Recent studies indicated that VIP innervation to the pineal gland may stem 
fiom the parasympathetic pterygopalatine ganglion or may be part of the central 
innervation via the pineal stalk. 
By influencing NA- or VIP-mediated stimulation of pinealocyte CAMP formation, a 
variety of other neurotransmitters (e.g. acetylcholine, serotonin, dopamine and y- 
aminobutync acid), neuromodulators (e.g. neuropeptide Y and prostaglandins) and 
hormones (e.g. estradiol, progesterone, testosterone and prolactin) and associated 
receptors may have a role in the fine-tuning of the nocturnal production of pineal 
melatonin. 
The regulation of the retinal melatonin production is not nearly as well understood 
as that of the pineal melatonin production (for reviews, see ref. 14-16,19-21). However, 
based on several recent findings in different vertebrate species, models for the neuronal 
and cellular regulation of melatonin production by retinal photoreceptors have been put 
forward. In these models the induction and activation of N-acetyltransferase, and thus 
melatonin production, is controlled by the intracellular CAMP formation and the 
calcium influx via voltage-sensitive channels [14,15,22,23]. These cellular events are 
regulated both by acute effects of light and by the oscillatory output of an endogenous 
ocular circadian clock. This clock is synchronized by the daily light/dark cycle, 
resulting in r h y t h c  synthesis of retinal melatonin with its maximum at night. As 
shown in Figure 4.3, which presents a model deduced from the above-mentioned 
models, the nocturnal enhancement of N-acetyltransferase activity in retinal 
photoreceptors results fiom an increased nocturnal CAMP formation and an increased 
nocturnal intracellular calcium concentration. In turn, these nocturnal increases result 
from a stirnulatory action of an endogenous ocular circadian clock as well as the 
absence of the influence of light. Namely, light-induced hyperpolarization of photo- 
receptors leads not only to a decreased calcium influx into these cells via voltage- 
sensitive channels, but also to an increased release of the important retinal 
neurotransmitter dopamine by retinal amacrine andlor interplexiform cells. This 
increased release can be explained in different ways. Most likely, the light-induced 
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Figure 4.3 Model for neuronal and cellular regulation of rhythc  melatonin production by retinal 
photoreceptors. Abbreviations: ATP, adenosine triphosphate; CAMP, cyclic adenosine 3',5'- 
monophosphate; D2, D2 receptor; DA, dopamine; E M ,  excitatory amino acid; GABA, y- 
aminobutyric acid; ML, melatonin; NAS, N-acetylserotonin; NAT, N-acetyltransferase. 
hyperpolarization prevents the release of an excitatory amino acid from photoreceptors. 
This results in a lowered GABA-mediated tonic inactivation of dopamine-releasing 
cells. Dopamine, once released, inhibits by stimulation of D2 receptors the cAMP 
formation of photoreceptors. Consequently, at night the inhibiting effect of dopamine 
on cAMP formation, N-acetyltransferase activity and melatonin production is almost 
absent due to its inhibited release by GABA. Melatonin, produced in reply to the 
nocturnal enhancement of N-acetyltransferase activity, inhibits retinal dopamine release 
even further. This inhibition is most likely mediated by the interaction of melatonin 
with specific melatonin receptors, located on dopamine-producing retinal cells (see 4.4). 
So, by inhibiting its own inhibitor, melatonin may enhance its own nocturnal 
production. It has been hypothesized that this reciprocal interplay between melatonin 
and dopamine might be responsible for the regulation of at least some retinal events, 
which are dependent on light-dark conditions, or follow circadian rhythci ty .  The 
entrainment of the endogenous ocular circadian clock by light appears to be partly 
mediated by a dopamine-dependent pathway. 
With the discovery of the pineal hormone melatonin its first observed physiological 
effect was demonstrated. This was its ability to lighten the skin of amphibians. 
Although melatonin has little effect on skin pigmentation in mammals, many other 
effects of melatonin, especially in connection with its function as an internal 
"Zeitgeber", i.e. its time-giving properties, have been described in mammals. Due to its 
ubiquitously acting character, it is beyond the scope of this introduction to describe and 
discuss all the physiological effects of melatonin. In this paragraph some of the most 
important and best studied physiological effects of pineal and retinal melatonin will be 
summarized. 
Over the years much evidence has accumulated regarding the influence of 
melatonin on virtually all components of the neuroendocrine system. Especially, its 
influence on the hypothalamic-pituitary-gonadal axis (i.e. the neuroendocrine- 
reproductive system) at all levels has been investigated in great detail (for reviews and 
references, see ref. 6,7,10,24-28). In mammals, effects of melatonin on reproduction 
have been identified in many species. In fact, melatonin, due to the changing seasonal 
message it sends to the reproductive system, is known to regulate annual fluctuations in 
breeding capability of photoperiodic mammals. Remarkably, melatonin synchronizes 
the annual cycle of reproduction in both long-day (short gestation period) and short-day 
breeders (long gestation period). In some mammalian species (e.g., hamster, a long-day 
breeder) melatonin clearly has antigonadotrophic actions (e.g., in male decreased testis 
weight, decreased spermato-genesis, depressed secretion of gonadotropins [luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH)] and prolactin and decreased 
testicular steroido-genesis and in female decreased ovarian and uterine weight, 
anovulation and acyclicity of secretion of gonadotropins). In others (e.g., sheep, a short- 
day breeder) it mainly seems to be progonadotrophic. In fact, melatonin should not be 
viewed as a strictly anti- or progonadotrophic factor. Rather, it is a hormonal messenger 
of the pineal gland that apprises the reproductive system, as well as other organ 
systems, of seasonal information (i.e. photoperiodic information). How this temporal 
information is subsequently used by a specific organ system depends on the 
responsiveness of that organ at the time it receives the information. This phenomenon is 
referred to as the passive nature of the melatonin message [lo]. Besides being a 
regulator of seasonal reproductive activities, melatonin is also a coordinating signal for 
circannual rhythms in other events in mammals. Such events include body weight, body 
temperature, coat color and hibernation [25,29]. These rhythms, ensuring that 
physiological changes are coordinated with seasonal changes in ambient conditions, are 
important elements in survival. 
In addition to its influence on seasonal reproduction in photoperiodic mammals, it 
has been shown that melatonin is involved in the reproductive life-span cycle of 
mammals, ie. sexual maturation (puberty) and the climacteric [7,26,28]. ALready 
around 1900 the possible role of the pineal gland in human puberty was recognized. 
Heubner was fust in describing a boy suffering from a pinealoma and showing signs of 
precocious puberty. Marburg coined the term "pubertas praecox" for this clinical 
syndrome and launched the hypothesis that the pineal gland, nowadays known to 
produce melatonin, regulates the onset of puberty. According to this hypothesis 
hypopinealism due to pineal degeneration would cause an advance of this event and, in 
reverse, hyperpinealism a delay. Little wonder that, in those days, the pineal gland was 
called "chastity gland" [30]. Although many investigations of the relation between 
melatonin production and puberty have been conducted in humans, the data are still 
equivocal. However, the results of a recent study in a man with hypogonadotropic 
hypogonadism, whose clinical abnormalities reversed spontaneously when melatonin 
secretion decreased, led to the conclusion that the patient's disorder, an extreme form of 
delayed puberty, was caused by hypermelatoninemia [31,32]. The most attractive 
explanation for this excessive melatonin production was pinealocyte hyperplasia, 
probably caused by excessive humoral andor neuronal stimulation or by 
hypersensitivity of the pinealocytes to normal stimulation. 
Beside its effects on the release of gonadotropins (LH and FSH) from the anterior 
lobe of the pituitary gland, directly or indirectly via controlling the release of 
gonadotrophic releasing hormone (GnRH) from hypothalamic neurons, melatonin has 
the ability to modify, generally in an inhibitory way, the secretion of all other classical 
hormones of the anterior lobe as well as the intermediate and posterior lobe of the 
pituitary gland (for reviews and references, see ref. 6,7,10,29). Consequently, melatonin 
regulates the functions of organs, inclusive glands like the gonads, the thyroid gland and 
the adrenal cortex. Additionally, endocrine factors less obviously regulated by the 
hypothalamo-pituitary system, such as insulin and gastrointestinal hormones, may also 
be modulated by melatonin. 
Recently, a considerable amount of evidence has accumulated suggesting a direct 
link between the pineal gland and the immune system (for reviews and references, see 
ref. 33-35). The accumulated evidence shows that the pineal gland, via its hormone 
melatonin, enhances immune function. Exemplary, melatonin gives rise to an enhanced 
antibody production in animals challenged with antigen. In addition, immune signals 
positively affect pineal function, e.g. interferon-y enhances P-receptor agonist- 
stimulated melatonin production in cultured rat pineal gland. Thus, according to this 
evidence, there exists a positive bidirectional interaction between the pineal gland and 
the immune system. The immunoenhancing capability of melatonin is very llkely an 
integral part of the neuroendocrine control over the immune system. 
Based on the early observation that pinealectomy has little effect on the circadian 
activity rhythms of mammalian species, many researchers thought that the pineal gland, 
and thus melatonin, is not involved in the mammalian circadian organization. However, 
the ability of exogenous melatonin, admmistered at the same time every day, to entrain 
circadian activity rhythms, such as wheel-running activity, locomotor activity and 
drinking, in mammals, especially rats and hamsters, in constant darkness, i.e. under 
free-running circumstances, is now well established (for reviews and references, see ref. 
36-38). It has been shown that entrainment of free-running circadian activity rhythms in 
rodents by melatonin only occurs when the onset of the active period coincides with the 
time of melatonin administration. This suggests that the entraining effect of melatonin is 
limited to a critical phase, i.e. a narrow window of sensitivity, in the circadian cycle. 
Collectively, the data of these studies show that the circadian clock underlying the 
activity rhythms, very likely located in the hypothalamic suprachiasmatic nuclei, is 
entrained by daily melatonin administration via daily phase advances. Additionally, 
melatonin appears to be able to entrain other circadian rhythms, such as body 
temperature, pineal N-acetyltransferase activity [39] and pineal melatonin production 
[40]. Beside the influence of melatonin on the circadian organization of mammalian 
animals, there is growing evidence that human circadian organization is profoundly 
melatonin-sensitive (for review and references, see ref. 37). Initial studies indicated that 
melatonin administered in the late afternoon or early evening to humans induced sleep, 
although these observations have been disputed. Many researchers have suggested that 
melatonin may not have direct effects on sleep processes, but instead may affect the 
timing of the sleep-wake cycle through its effects on circadian organization. Namely, 
exogenous melatonin phase-advances the circadian rhythms of several biochemical and 
behavioural correlates including alertness, sleep, blood cortisol, body temperature, and 
melatonin itself. 
As already mentioned, retinal melatonin has very likely only paracrine effects. 
Retinal melatonin plays certainly an important role in retinal events, which are 
dependent on light-dark conditions, or which exhibit circadian rhythci ty .  Thus, 
melatonin acts as a signal for darkness and/or nighttime, i.e. it induces dark-adaptive 
photoreceptor movements (cone elongation and rod contraction), aggregation of melanin 
pigment granules in retinal pigment epithelial cells and activation of disc shedding in 
rod photoreceptor outer segments [41]. Some investigators hypothesize that melatonin 
indirectly brings about these functional changes in the retinas via inhibition of retinal 
dopamine release [41]. Particularly, dopamine mediates the opposite functional changes 
to adapt retinas to light andor daytune. Other investigators suggest that the effects of 
retinal melatonin may not be limited to the doparninergic system. Other neuro- 
transmitter pathways, such as acetylcholine and GABA, may also be directly involved 
in mediating the paracrine effects of retinal melatonin [42]. 
4.3 CLINICAL IMPLICATIONS AND PERSPECTIVES OF MELATONIN 
Considering the profound influence of melatonin on the mammalian circadian 
organization, as well as on a variety of endocrine and nonendocrine systems in 
mammals including man, it seems clear that malfunctioning of the pineal gland, and 
consequently a disrupted melatonin message, can play an important role in a variety of 
pathophysiological circumstances. However, up to now it has not been established for a 
single pathophysiological state whether a disrupted melatonin message is the cause, an 
effect, or even related to the condition. 
Disorders of the reproductive system, whch are associated with hyper- or hypo- 
melatoninism, and thus possibly can be treated through correction of this state, e.g. by 
the administration of a melatonin-receptor antagonist or a melatonin-receptor agonist 
(see 4.5), respectively, include hypothalamic amenorrhea in females, oligo- or aspermia 
in males, and delayed or advanced puberty in females as well as males [9,43]. Clinical 
trials have already demonstrated that melatonin itself or in combination with a synthetic 
progestin can act as a contraceptive agent in females by inhibiting ovulation [44,45]. In 
addition to its mediation of certain pathophysiologies of the neuroendocrine- 
reproductive axis, melatonin may also be implicated in the malfunctioning of other 
endocrine organs as well, e.g. the adrenal cortex and the thyroid gland [9,46,47]. 
Besides, melatonin has tentatively been related to a variety of mood disorders [9,48- 
501. Low melatonin syndrome, also called depressive hypomelatoninemia, has been 
described in a subgroup of depressed patients and may prove to be diagnostic for the 
condition. Other affective disorders in which melatonin is speculatively involved 
include schizophrenia, obsessive-compulsive disorder, manic-depressive disease, and in 
particular seasonal affective disorder (SAD), also called winter depression. This type of 
depression, accompanied by disturbed circadian and circannual rhythms, is 
characterized by recurring symptoms like weight gain, hypersomnia, carbohydrate 
craving and depressed mood during short day seasons and can effectively be treated by 
light therapy. Based on the results of a study comparing evening with morning artificial 
bright light exposure in the treatment of SAD, Lewy and colleagues propose that the 
antidepressant effect of artificial bright light depends on the timing of the 
administration. Morning bright light therapy is more effective than evening bright light 
therapy [48,51]. The greater effectiveness of morning bright light exposure in SAD 
patients results from its phase-advancing effects on the evening onset of melatonin 
production and consequently other circadian rhythms, which they presume to be 
abnormally phase-delayed in such patients [51]. However, the results of this study were 
not c o n f i e d  by other investigators [49]. Thus far, no convincing evidence has been 
presented that melatonin is positively involved in the response of SAD patients to 
phototherapy. Nevertheless, if melatonin is involved, it is possibly through its time- 
giving properties. 
In addition, a disrupted melatonin message may not only be involved in sleeping 
disorders, such as delayed sleep-phase syndrome, advanced sleep-phase syndrome, non- 
24 hour sleep-wake disorder and sleep disturbances in the elderly, but also in 
disturbances with disrupted circadian rhythms, such as blindness, jet-lag (inter- 
continental flight dysrhythrma) and shift-work syndrome. Melatonin seems to be at least 
a mild sleep-inducing agent of short duration in healthy adults without the adverse side- 
effects of classic hypnotics, such as the benzodiazepines [52]. It may be particularly 
helpful in causing restful sleep in the elderly, who suffer from poor sleep quality. A 
gradual deterioration of the melatonin rhythm takes place during ageing [18] and this 
deterioration probably causes among other things the sleep disturbances in the elderly. 
Successful treatment of delayed sleep-phase syndrome patients with melatonin has 
already been reported twice [53,54]. In addition, melatonin has been used with success 
in the clinic to entrain circadian rhythms, especially the sleep-wake cycle, of blind 
patients to the appropriate chronological 24-hour day [55-571. It has also been shown to 
ameliorate the negative psychological and physiological effects of jet-lag [58-6 11. Thus, 
in these kind of disorders and disturbances melatonin, or a melatonin-receptor agonist, 
may show to have the ability to h c t i o n  as a chronobiotic (i.e. a substance that can act 
as a synchronizer to reset the phase of circadian rhythms) [62]. Therapeutically, this 
would mean the re-entrainment of short-term dissociated or long-term desynchronized 
circadian rhythms. In addition, the prophylactic treatment with melatonin or a 
melatonin-receptor agonist may prevent the disruption of circadian rhythms upon an 
environmental insult [62]. 
As already mentioned above, in advanced age a progressive attenuation of the 
melatonin rhythm, probably caused by a gradual depression in pinealocyte j3-adrenergic 
receptor density, takes place. This relative deficiency of melatonin in advanced age has 
not only been related to age-related disease processes, such as immunodeficiency, 
tumor growth, hypertension, senile diabetes, sleep inefficiency, Alzheimer's disease, 
and psychiatric disorders, but has also been associated with longevity itself (for reviews 
and references, see ref. 18,62-64). Food restriction is a treatment that markedly 
improves the general physiological state of an animal (e.g. less mammary gland and 
epidermal tumors) and increases its life span. Furthermore, it significantly delays the 
degeneration of the animal's melatonin rhythm. One can hypothesize that the preserved 
melatonin rhythm accounts for the prolonged longevity. In favour of this hypothesis is 
the remarkable finding that melatonin, added to the drinking water of mice during 
darkness, retards the ageing syndrome and prolongs life span by 20% [65]. The 
question, how a preserved melatonin rhythm by food restriction or the administration of 
melatonin can prolong longevity, can only be answered speculatively. First, prolonged 
longevity possibly results indirectly from melatonin's alleged immunostimulatory 
effects (for reviews, see ref. 33-35) and/or oncostatic actions (for reviews, see ref. 
66,67). Even if melatonin does not increase life expectancy via these functions, it may 
improve the quality of life in this way. Second, melatonin may delay ageing by its 
generalized beneficial effects on metabolic activity, which probably are mediated by its 
chronobiotic effects on the circadian pacemaker system [62]. Namely, these 
chronobiotic effects of melatonin may prevent the age-related internal desynchrony, 
which results fi-om instability within the circadian system, as life progresses. Third, 
melatonin may protect directly against ageing by acting as an endogenous fi-ee radical 
scavenger [64]. Although no defintive link between ageing and melatonin has been 
established yet, its classification as an anti-ageing or juvenile hormone and as a 
potential "fountain of youth" should not be categorically dismissed [18]. The data 
accumulated to date encourage work in a variety of progeric syndromes, which closely 
resemble ageing, or could be defrned as accelerated senescence [68]. Moreover, these 
data certainty justifL serious consideration of the possibility that supplemental 
melatonin, or a melatonin-receptor agonist, may be beneficial during ageing [18,62]. 
Keeping the oncostatic actions of melatonin in mind [66,67], it has been proposed 
that a depression of endogenous melatonin is possibly involved in the aetiology of 
human cancers, and not alone of age-related ones. The finding that hormone-dependent 
types of malignancy, like breast and prostate cancer, are associated with a significant 
reduction of the circadian amplitude of the melatonin rhythm, supports this hypothesis. 
Thus, melatonin could be of therapeutic value in the treatment of tumors. Melatonin's 
advantageous actions in the case of hormone-dependent tumors could be explained by 
its control over the hypothalamic-pituitary-gonadal axis (e.g. inhibition of estrogen 
production at gonadal level and of prolactin at adenohypophyseal level), while its 
advantageous actions in the case of hormone-independent tumors could be explained by 
its influence on immunological processes (e.g. stimulation of natural killer cell activity). 
Ultimately, in respect of the clinical implications and perspectives of melatonin, it 
should be mentioned that patients, suffering from the skin disease psoriasis, have 
extremely low night time levels of melatonin and that administration of melatonin, 
topically or orally, has been shown to have beneficial effects in such patients [69]. In 
addition, it has been suggested that sudden Infant death syndrome (SIDS), may be 
related to the failure of the maturation of the biological clock and to the development of 
the melatonin rhythm during the first year of life [64]. 
Summarizing, melatonin and melatonin-receptor agents (see 4.5) unequivocally 
possess therapeutic potential in a gamut of pathophysiological circumstances. 
Considering the profound influence of melatonin on the circadian organization, i.e. its 
synchronizing and time-giving properties, the outcome of a particular clinical 
investigation with melatonin or a melatonin-receptor agent will certainly be affected by 
the time of the day it is given and the duration of the treatment [8]. 
Responding to the melatonin message requires that this message can be deciphered. 
To respond, cells presumably must be provided with specific receptors for melatonin. 
During many years progress in this area of melatonin research was slow due to the lack 
of the necessary pharmacological tools to study and manipulate these target sites of 
melatonin. Recently, however, due to the introduction of 2-[1251]iodomelatonin (see 
4.5), a high-affinity, high specific activity radioligand for melatonin binding sites [70- 
741, the advent of advanced receptor techniques (e.g. quantitative autoradiography), the 
development of quantitative in vitro melatonin receptor-linked bioassays (e.g. the 
inhibition of retinal dopamine release by melatonin [75-791) and the availability of 
some, mostly indolic, melatonin-receptor agents (see 4 4 ,  significant advances have 
been made in our understanding of specific melatonin receptors and the mode of action 
of melatonin at the cellular level. Nevertheless, considerable controversy still exists in 
relation to several aspects of this area of melatonin research. 
4.4.2 LOCALIZATION A D FUNCTION 
To date, by the use of the above-mentioned pharmacological tools, putative 
melatonin receptors have been identified in a variety of brain areas and peripheral 
organs of many different vertebrate species, including mammals (for reviews and 
references, see ref. 9,230-86). Depending on the species investigated, putative melatonin 
receptors in the brain have been found to be either quite widespread (e.g. buds) or to 
have a rather discrete distribution (e.g. mammals). In general, as one ascends the 
phylogenetic scale, central melatonin receptors become progressively more limited in 
their apparent distribution. In mammals, of which rodents are especially well studied, 
the most frequently mentioned brain areas for the location of putative melatonin 
receptors include the suprachiasmatic nuclei (SCN) of the hypothalamus and the pars 
tuberalis (PT) region of the anterior pituitary gland - originally reported as the median 
eminence (ME) region of the hypothalamus - [73,74,87-1011. It should be noted, 
however, that there seem to exist subtle species differences in the general distribution 
pattern. For example, putative melatonin receptors are seemingly absent in the SCN of 
the ferret and related carnivora, while they are abundantly found in the PT region of 
these mammalian species [102,103]. In contrast, human putative melatonin receptors 
have only been reported in the SCN [87]. 
The mammalian SCN are nowadays considered to be the site of the endogenous 
circadian clock, which generates a variety of circadian rhythms, including the pineal 
melatonin production. Thus, it seems likely that melatonin receptors in the SCN are 
responsible for the mediation of melatonin's lduence on the mammalian circadian 
organization. Due to contradictory data, as reported for several mammalian species, it is 
unclear at this moment whether these receptors also play a role in melatonin's effects on 
mammalian reproduction [8 1,851. Melatonin receptors in the pituitary PT region, due to 
their apparent strategic position, i.e. in close proximity to the primary portal plexus of 
the hypothalamic ME region, an important anatomic interface between the neuronal and 
endocrine systems, are assumed to mediate melatonin's involvement in the regulation of 
neuroendocrine systems, especially the neuroendocrine-reproductive system [81,85]. 
However, little is known about the exact role of this region of the pituitary. It is possible 
that factors released from melatonin-receptor containing cells of the PT region act in a 
paracrine manner on nearby neuroendocrine terminals of hypothalamic neurons in the 
extemd zone of the ME region in order to limit the secretion of hypothalamic 
regulatory hormones (e.g. LHRH). Alternatively, these paracrine factors could enter the 
capillaries of the primary portal plexus of the ME region and pass to the cells of the 
anterior pituitary gland (pars distalis) to modify directly the secretion of trophic 
hormones (e.g. LH, FSH and prolactin). Finally, considering the blood flow patterns in 
the anterior and medial basal hypothalamus, it is possible that these paracrine factors 
could have direct access to the cell bodies of the hypothalamic releasing and inhibiting 
hormone neurons (e.g cell bodies of LHRH neurons in the hypothalamic preoptic area) 
[851. 
In some mammals, including primates, putative melatonin receptors were also 
discovered in other neuronal and nonneuronal brain structures, like the choroid plexus 
of the 4th ventricle, the area postrema, certain hypothalamic areas (e.g. preoptic area), 
certain thalamic nuclei (e.g. paraventricular nuclei), cerebral cortical stuctures, the 
hippocampus, the amygdala and the retinas [88,92,93,95,96,98-101,104-1061. 
Speculatively, melatonin may play a role in the regulation of some autonomic functions, 
such as cardiovascular control, food intake and sleep-wake-cycles, through the 
interaction with melatonin receptors localized in the area postrema [85]. Additionally, 
in the control of circadian performance rhythms, such as alertness, learning and 
depressiveness through the interaction with melatonin receptors localized in limbic 
thalamic nuclei [104]. Finally, in the release of the important retinal neurotransmitter 
dopamine and the adaptation of the retina to darkness through the interaction with 
retinal melatonin receptors [105]. 
Putative peripheral melatonin receptors seem to occur particularly in those organs 
of vertebrates, which have a role in reproduction or which are important in the immune 
system. Thus, they were shown in the testes, the ovaries, and the bursa of Fabricius of 
birds and in the thymus and the spleen of birds, as well as mammals, and on human 
lymphocytes [107-1121. Other locations of peripheral melatonin receptors seem to be 
the Harderian gland, the gastrointestinal tract and the vasculature of the basal brain 
arteries, forming the circle of Willis, and the caudal arteries [113-1151. The last- 
mentioned ones could mediate melatonin's action on the tone of these arteries, causing 
circulatory adjustments in these arteries, which are believed to be involved in thermo- 
regulation [ 1 151. 
The density of putative central and peripheral melatonin receptors varies not only 
with species and location, but it is also affected, in some locations of certain species, by 
environmental circumstances, developmental stage, ageing and endocrine status [9,8 1, 
861. For example, it has been shown recently that circumstances, like constant 
illumination and pinealectomy, known to decrease the concentration of circulating 
melatonin, result in an increase in the density of putative melatonin receptors in the 
SCN and PT region of rodents [ 1 16- 1 181. The increase, induced by pinealectomy, could 
be counteracted by the administration of melatonin 11 181. These observations suggest a 
direct, addaptive effect of melatonin on the density of its own receptor. It was found 
that in both above-mentioned structures of the rat daily variations in the density of the 
putative melatonin receptors exist. These changes are inversely correlated with the 
circadian melatonin rhythm and disappear in constant illumination. Ths  may implicate 
that the circadian melatonin rhythm induces the daily variations in these densities, 
probably by a mechanism of up- and down-regulation of the putative melatonin 
receptors by melatonin itself [118,119]. Beside these daily density rhythms, a seasonal 
variation in the number of putative melatonin receptors in the PT region of the male 
European hamster has been described (maximum number in spring and early summer) 
[120]. This seasonal variation seems to be independent of gonadal status, i. e. circulating 
testosterone levels. This would be expected for a photoperiodic, seasonally breeding 
animal and this seasonal variationmay thus result from factors, such as the annual 
change in photoperiod, temperature, hibernation and nocturnal melatonin profile. The 
exact nature of these interactions, however, remains to be clarified. 
Putative melatonin receptors, as labelled with 2-[1251]iodomelatonin, have been 
characterized pharmacologically with respect to kinetic properties and specificity of 
ligand binding in a large variety of mammalian tissues (for reviews and references, see 
ref. 80-86). Although there is sometimes a lack of consistency between the results of 
different studies, the overall characteristics of these putative melatonin receptors are 
generally in good agreement with each other. 
In most cases, characterization by saturation, kinetic and competition experiments 
demonstrated that the specific binding of 2-[1251]iodomelatonin is rapid, stable, 
saturable, reversible, of high affinity (Kd in low picomolar range) and specifically 
displacable. Melatonin has a much higher affinity than other compounds, such as N- 
acetylserotonin, 5-methoxytryptamine, serotonin, dopamine, norepinephrine and 
acetylcholine. Thus, the criteria for binding to putative melatonin receptors are fulfilled. 
In addition, pharmacological profiling of these putative melatonin receptors by 
determining the ability of a range of indolic compounds (see 4.5) to displace specific 2- 
[1251]iodomelatonin binding revealed that in most vertebrate tissues, as shown in Table 
4.1, one deals with the same type of putative melatonin receptor. The general order of 
relative aff i t ies  is: 2-iodomelatonin (2-1-ML) > 2-bromomelatonin (2-Br-ML) 2 2- 
chloromelatonin (2-Cl-ML) > 6-chloromelatonin (6-Cl-ML) > melatonin (ML) > 6- 
hydroxymelatonin (6-OH-ML) > N-acetylserotonin (N-Ac-5-HT) > 5-methoxy- 
tryptophol (5-MTol) > 5-methoxytryptamine (5-MT) > serotonin (5-HT). Where tested, 
guanine nucleotides, such as GTP and the nonhydrolyzable analogue GTPyS, and 
monovalent cations, such Na+ and ~ i + ,  generally modulated the specific binding of 2- 
[1251]iodomelatonin to this type of putative melatonin receptor [83,84,98,101,117,121- 
1281. This modulation involved mostly the conversion of this receptor to a state, which 
exhibits about a tenfold lower affinity for 2-[1251]iodomelatonin. Lower assay 
temperatures than normally used in 2-[1251]iodomelatonin binding experiments cause 
probably the same conversion [128]. These observations suggest that this type of 
putative melatonin receptor belongs to the superfamily of membrane-bound G-protein- 
coupled receptors, which can exist in two affinity states, i.e. an agonist-induced high- 
affinity state, when coupling to the G-protein occurs, and a low-affinty state, when 
coupling to the G-protein is disrupted. Since melatonin concentrations, normally found 
in body fluids of the various species studied, are in the high picomolar or low nanomolar 
range, this type of putative melatonin receptor seems to be of physiological relevance. 
Table4.1 Comparison of inhibition constants (K,) of a range of compounds for 2-[125~]iodo- 
melatonin binding sites. Abbreviations: OT, optic tectum; SCN, suprachiasmatic nuclei; PT, 
ars tuberalis; PC, parietal cortex. %cubation temperature 0 OC instead of 25 OC or 37 OC. 
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Beside this type of putative melatonin receptor, designated ML-1 receptor [80,84], 
another type of putative melatonin receptor, designated ML-2 receptor [80,84], has been 
described. This second type, to date only localized in hamster brain [130-1341, has 
different binding as well as pharmacological characteristics, as compared to ML-1 type. 
The specific 2-[1251]iodomelatonin binding is of moderate affinity (Kd in low and 
medium nanomolar range) and the order of relative amities of a range of indolic 
compounds is quite special. Most notably, melatonin, N-acetylserotonin and 6-methoxy- 
melatonin are almost equipotent in displacing specific 2-[1251]iodomelatonin binding 
from this type of putative melatonin receptor [130,132]. Additionally, the selective a l -  
adrenoceptor antagonist prazosin, incorporating two methoxy-groups on its main ring 
structure, is also a displacer of relative high potency [13 1,134,1351. However, on the 
basis of present evidence it is difficult to decide if this type of putative melatonin 
receptor has physiological significance as a specific melatonin receptor. 
Implicit in the term "receptor" is a functional response, which is manifested as a 
consequence of receptor occupation by an agonist. Thus, putative melatonin receptors 
can only be classified as actual melatonin receptors, if they are correlated to functional 
responses. The first functional response associated with the stimulation of a melatonin 
receptor was the melatonin-induced aggregation of melanin granules in amphibian skin 
melanophores causing slun-lightening (for review, see ref. 136). Already at the end of 
the 1960's it was shown that melatonin reverses not only the melanocyte-stimulating 
hormone-induced (MSH-induced) darkening of amphibian skin, but also inhibits the 
MSH-induced increases in cyclic adenosine 3',5'-monophosphate (CAMP) content of 
melanophore-rich amphibian skin [137]. Recently, it was shown that melatonin 
counteracts the forskolin-induced dispersion of melanin granules in melanophores. 
Forskolin is known to stimulate directly the activity of the enzyme adenylyl cyclase. In 
addition, it was demonstrated that this action of melatonin could be blocked by pertussis 
toxin, which selectively inactivates inhibitory guanine nucleotide-binding regulatory 
proteins (Gi-proteins) through ADP-ribosylation of the a;-subunit [138]. On the basis of 
these observations it was hypothesized that melatonin affects amphibian skin 
pigmentation through the stimulation of a specific melatonin receptor, which is linked 
via a Gi-protein to the enzyme adenylyl cyclase and, consequently, in an inhibitory way 
to the production of the second messenger CAMP. 
Very recently, the melatonin-mediated inhibition of the forskolin-stimulated cAMP 
accumulation in the PT region and some other brain areas of a variety of vertebrates, 
including mammals, was elucidated as a second functional response associated with the 
stimulation of a specific melatonin receptor (rat ME/PT explants [139]; hamster MEPT 
explants [124]; cultured ovine PT cells [140]; mouse MEIPT explants [141]; hamster 
hypothalamus homogenates [142]; chicken forebrain synaptosomal membranes [143]; 
chicken retinal membranes [143]; rabbit parietal cortex explants [127]; frog optic 
tectum explants [144]). In some of these tissues, this inhibition was shown to be 
blocked by pertussis toxin, indicating that this inhibition of adenylyl cyclase activity by 
melatonin was mediated by a Gi-protein-coupled melatonin receptor [124,127,143]. 
However, it has been difficult to establish a physiological cellular function of this 
melatonin-mediated inhibition of adenylyl cyclase activity in the tissues studied. A 
possible function in the PT region could be the modulation of the secretion of a PT cell- 
specific product. In addition, it was found that melatonin in the neonatal rat anterior 
pituitary gland, known to possess a reasonable density of putative 2-[1251]iodo- 
melatonin-labelled melatonin receptors, which decreases within the first 30 postnatal 
days to 10% of the neonatal value [145], inhibits basal and LHRH-induced cAMP 
accumulation [86,139,146]. This inhibition could mediate the inhibitory effect of 
melatonin on LHRH-induced LH-release by the neonatal rat anterior pituitary gland 
[147]. However, this inhibitory effect of melatonin on LHRI-I-induced LH-release could 
also be mediated by the negative influence of melatonin on the LHRH-induced 
accumulation of other second messengers, such as diacylglycerol [148], arachidonic 
acid [148] and ca2+ [149], as demonstrated in this tissue. 
Another functional response, correlated to the stimulation of a specific melatonin 
receptor is the melatonin-induced inhibition of the ~a2+-dependent dopamine release 
from retinas of different vertebrates, e.g. rabbit, chicken and frog [75-79,1501. It is 
presently not totally clear which second messenger system transduces this effect of 
melatonin. Some preliminary studies suggest that stimulation of the specific melatonin 
receptor decreases the availibility of ca2+ for the secretory process, perhaps by 
affecting the entry of ca2+ into the dopaminergic nerve terminal [84]. This functional 
response led to the first in-depth quantitative pharmacological characterization of a 
functional melatonin receptor [75,76,80,83,84]. This receptor is specifically activated 
by picomolar concentrations of melatonin and shows a pharmacological profile, which 
corresponds very well with that of the 2-[1251]iodomelatonin-labelled melatonin 
receptors of the ML-1 type [72,80]. Quantitative pharmacological profiling of the other 
functional melatonin receptors, i.e. the receptors mediating the aggregation of melanin 
granules in amphbian melanophores and the inhibition of forskolin-stimulated CAMP 
accumulation in various vertebrate tissues, has not been extensively conducted. 
However, initial profiling studies suggest that these melatonin receptors belong to the 
ML-1 type [84,124,139,151-1531. 
Future advances in the characterization of melatonin receptors will certainly involve 
the cloning by molecular biologists of one or more genes, encoding melatonin receptors. 
These genes will be valuable tools, allowing not only the determination of the primary 
amino acid sequences of melatonin receptors, but also the expression of these receptors 
in well-defined cellular systems in order to study their functions at the cellular level. 
Knowledge of the structural features, which are important for the biological activity 
of a substance that exerts its effects via interaction with a specific receptor, and the 
availability of analogues, which mimic (agonists) or counteract (antagonists) the effects 
of this substance, are prerequisites for a better understanding of the mode of action of 
this substance. This is also valid for melatonin. Keeping this in mind, it is easily 
understood that very soon after the chemical identification of melatonin as N-acetyl-5- 
methoxytryptamine, the first structure-activity-relationship studies (SAR studies) 
around melatonin and simple melatonin analogues were performed. In addition, the 
search for novel melatonin-receptor agonists and antagonists was initiated. Especially, 
the introduction of 2-[1251]iodomelatonin-binding assays and quantitative functional in 
vitro receptor bioassays for melatonin, based on the above-mentioned functional 
responses (see 4.4.3), have stimulated this kind of melatonin research. 
The first chemical modifications on melatonin (N-acetyl-5-methoxytryptamine, 1) 
were performed by Lerner and co-workers, the discoverers of melatonin [4,154]. 
Utilizing the amphibian skin-lightening action of melatonin as a functional bioassay, i.e. 
determination of the rnininal effective concentration of a compound required to lighten 
frog skin previously darkened with MSH, they demonstrated already that the N-acetyl 
group and the 5-methoxy group are essential structural entities of melatonin to elicit its 
specific biological activity; N-acetylserotonin (2), N-acetyltryptamine (3) and 5-methoxy- 
tryptamine (4) had a much weaker skin-lightening action than melatonin. They showed 
also that replacement of the 5-methoxy group of melatonin by a 5-ethoxy group (5) or 
Chart 4.3 Chemical structures of melatonin (I), N-acetylserotonin (2), N-acetyltryptamine (3), and 5- 
methoxytryptamine (4). 
5-acetoxy group (8) results in less active tryptamides than melatonin. In addition, 
replacement of the N-acetyl group of melatonin by a N-propionyl group (14) or a N- 
butyryl group (15) results in equally effective skin-lighteners as melatonin, thus 
melatonin-receptor agonists. Finally, that substitution of the side-chain nitrogen of 
melatonin with a methyl-group, i.e. N-acetyl-N-methyl-5-rnethoxytryptamine (21), is 
detrimental to melatonin's skin-lightening action. The results of later performed SAR 
studies of melatonin analogues on the aggregation of melanin granules in melanophores 
of amphibians [151,153,155-1571 and fish [I581 using different assay methods are in 
good agreement with the results of these early performed SAR studies [4,154]. 
Chart 4.4 Chemical structures of 5-substituted N-acetyltryptamines (5-12), N-acyl-5-methoxy- 
tryptamines (13-20), and N-acetyl-N-methyl-5-methoxytryptamine (21). 
Especially, a recently executed SAR study, which used single cultured Xenopus 
laevis melanophores to measure in vitro the pigment aggregation responses to melatonin 
and some analogues, showed quantitatively that replacement of the N-acetyl group of 
melatonin by a N-formyl group (13) results in a compound without pigment-aggregation 
activity, that the N-propionyl analogue (14) is equally effective as melatonin to induce 
pigment aggregation, and that larger side-chain substitutions, i. e. N-butyryl-5-methoxy- 
tryptamine (15), N-isobuty~yl-5-methowtarnine (16), and N-valeroyl-5-methoxy- 
tryptamine (17), lead to a marked, progressive loss of pigment-aggregation activity as 
the length of the side-chain increases, ultimately resulting in inactive analogues, such as 
N-caproyl-5-methoxytryptamine (19) [153]. Thus, these findings suggest that the size of 
the N-acyl substituent is very important for an optimal interaction with a melatonin 
receptor. Additionally, this SAR study revealed quantitatively that other substituents, 
such as hydrogen (3), hydroxy (2), benzyloxy (7), and methyl (lo), at the 5-position of 
the indole nucleus than the methoxy group of melatonin give compounds, which are 
unable to induce pigment aggregation [153]. Hence, suggesting that the size and/or 
electronic properties of the substituent at this 5-position islare critical for melatonin- 
receptor agonist activity. These suggestions were supported by the activity of N- 
butyryl-5-methoxytryptarnine (15) and the decreased activity or inactivity of N- 
pivaloyl-5-methowtarnine (It?), N-benzoyl-5-methoxybyptarnine (20), N-acetyl-5- 
ethoxytryptamine (5), N-acetyl-5-propoxytqptamine (6), N-acetyl-5-benzyloxy- 
tryptamine (7), N-acetyl-5-acetoxyt~yptamine (a), and N-acetyl-5-t-butyldimethyl- 
silyloxytryptamine (9) in an earlier performed SAR study, employing a melatonin- 
specific, sensitive in vivo fish bioassay [158]. The importance of the size and/or 
electronic properties of the substituent at the 5-position for melatonin-receptor agonist 
activity was also demonstrated in vivo by the inability of N-acetyl-5-fluorotryptamine 
(11) and the ability of N-acetyl-5-bromotryptamine (12), which was almost similar to 
that of melatonin, to inhibit the sexual development in prepubertal male rats [159]. As 
far as tested, the potencies of the above-mentioned compounds, especially N-acetyl- 
serotonin (2) and 5-methoxytryptamine (4), to compete for 2-[1251]iodomelatonin 
binding to different tissues (see Table 4.1, inclusive references) [84,160] generally 
correlated well with their activities in the above-mentioned assays and some other 
assays, e.g. inhibition of LHRH-stimulated release of LH [161], inhibition of retinal 
dopamine release [72,76], and inhibition of CAMP production [139]. 
With the intention to develop compounds with similar physiological properties as 
melatonin, thus melatonin-receptor agonists, but greater resistance to metabolism - 
melatonin is very rapidly metabolized to 6-hydroxymelatonin (22) in the liver [162] and 
to N-acetyl-5-methoxykynurenamine in the CNS [I631 (see Chart 4.2); melatonin has 
approximately a plasma half-life of 12 min in rats [164]-, Flaugh and colleagues 
synthesized in 1979 a variety of melatonin analogues, particularly analogues bearing 
substituents at the 6-position [165]. They found that 6-fluoromelatonin (23), 6-chloro- 
melatonin (24), and the N-propionyl (27) and N-butyryl (28) analogues of 6-chloro- 
melatonin possess better in vivo ovulation-blocking activities than melatonin. On the 
Chart 4.5 Chemical structures of 6-substituted N-acyl-5-methoxyt~yptamines (22-28) 
basis of the amphibian skin-lightening activity of 6-chloromelatonin (24) and the 
general pattern of the SAR, e.g. inactivity as ovulation blockers of all analogues 
involving a deviation from the 5-methoxy group, they concluded that these compounds 
are melatonin-receptor agonists and not merely enhancers of the endogenous melatonin 
level through an antimetabolite action [165]. Supplementary research revealed that 6- 
fluoromelatonin (23) and 6-chloromelatonin (24) very likely exert their in vivo anti- 
ovulatory action through the inhibition of the proestrous LH surge and that the 
metabolic stability of 6-chloromelatonin (24) is better than that of melatonin, but 
metabolism still occurs relatively rapidly. The plasma half-life of 6-chloromelatonin 
was found to be 27 min [166]. If one accepts that 6-halogenation effectively blocks 6- 
hydroxylation, it follows that oxidative cleavage of the indole ring (C2-C3 bond) is also 
quite facile [165,166]. Of the other melatonin analogues synthesized by Flaugh and 
colleagues only 2-methylmelatonin (29) is a equally effective to melatonin as in vivo 
ovulation blocker. Analogues such as 6-methylmelatonin (25), 1-methylmelatonin (30), 
and 4-chloromelatonin (31) appeared to be inactive as ovulation blockers. 
OCH, OCH, 
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Chart 4.6 Chemical structures of 2-methylmelatonin (29), 1-methylmelatonin (30), and Cchloro- 
melatonin (31). 
Martin and colleagues, also searching for melatonin analogues protected against 6- 
hydroxylation, but still displaying physiological activity similar to melatonin, 
demonstrated that 6-fluoromelatonin (23) [167] retains the ability of melatonin to 
inhibit in vitro the LHRH-stimulated release of LH by neonatal rat anterior pituitary 
gland, while 6-hydroxy-melatonin (22) has lost this ability [168]. Thus, they showed 
that 6-fluoromelatonin (23) is really a melatonin-receptor agonist. At that time several 
studies had already shown that 6-hydroxymelatonin (22) is almost inactive as skin- 
lightener 1151,1561, although one study claimed that 6-hydroxymelatonin (22) was 
almost as effective as melatonin to induce pigment aggregation [157]. Further studies 
with 6-substituted melatonin analogues, such as 6-hydroxymelatonin (22), 6- 
fluoromelatonin (23), 6-chloromelatonin (24), 6-methylmelatonin (25), and 6-methoxy- 
melatonin (26), using different melatonin-responsive assays demonstrated that of these 
compounds the 6-halogenated ones mimic most effectively melatonin [72,76,84,124, 
153,158,159,169-1721. 
Based on the observations that 6-chloromelatonin (24), a melatonin analogue 
protected against 6-hydroxylation, is as active as melatonin in the in vivo fish bioassay 
and that 2,3-dihydromelatonin (32), a compound protected against oxidative cleavage of 
the C Z - C ~  bond, is only 10-fold less active as melatonin in the same assay, Frohn and 
colleagues postulated that the melatonin analogue combining both structural elements 
(33) would be a melatonin-receptor agonist of reasonable activity with a markedly 
increased half-life as compared with melatonin [158]. This postulation was 
substantiated by Kennaway and colleagues, who showed that 6-chloromelatonin (24), 
2,3-dihydromelatonin (32), and 6-chloro-2,3-dihydromelatonin (33) have potent 
prolactin-lowering activity in sheep 11711 and that all three melatonin analogues are 
potent blockers of puberty in male rat [159]. Another melatonin analogue, in which the 
two major points of metabolism are blocked, but still possesses the physiological 
properties of melatonin, is 6,7-dichloro-2-methylmelatonin (34) [172], a combination of 
the two melatonin-receptor agonists 6-chloromelatonin (24) and 2-methylmelatonin 
(29). 
OCH, OCH, OCH, 
C I 0 
Chart 4.7 Chemical structures of 2,3dihydromelatonin (32), 6-chloro-2,3dihydromelatonin (33), and 
6,7-dichloro-2-methylmelatonin (34). 
In search of a radioactive iodinated tracer for a melatonin radioimmunoassay, 
Vakkuri and colleagues showed that melatonin can be directly iodinated at the 2- 
position of the indole ring [70,71]. Beside the fact that 2-[1251]iodomelatonin turned 
out to be a high-affinity radioligand of high specific activity for putative melatonin 
receptors [72-741, the nonradioactive melatonin analogue 2-iodomelatonin (37) was 
Chart 4.8 Chemical structures of 2-halogenated N-acyl-5-methoxytryptamines (35-39) 
identified in vitro as well as in vivo as a very potent indolic melatonin-receptor agonist 
[72,74,152,172,173]. Based on this activity two other 2-halogenated melatonin 
analogues, z.e. 2-chloromelatonin (35) and 2-bromomelatonin (36), were developed and 
shown to compete potently for 2-[1251]iodomelatonin binding and to act in vitro as well 
as in vivo as potent melatonin-receptor agonists [91,152,173-1751. Replacement of the 
N-acetyl group of 2-iodomelatonin (37) by a N-butyryl group (38) resulted in a 
melatonin-receptor agonist, which is even more potent than 2-iodomelatonin (37) [176]. 
The intention to incorporate a chemically reactive group into 2-iodomelatonin (37) in 
order to obtain an irreversible-binding melatonin-receptor affmity label led to the 
develop-ment of N-bromoacetyl-2-iodo-5-methoxytryptamine (BIM, 39) [177,178]. The 
radio-iodinated form of this melatonin analogue ( [ 1 2 5 ~ ] ~ ~ ~ )  was used for the 
identification of melatonin-binding proteins in rat and hamster brain synaptosomes 
[177,178]. However, recently retrieved data provided no evidence that [ ~ ~ ~ I I B I M  
affinity labels specific melatonin-binding proteins in chicken brain [179]. 
Recent SAR studies revealed that the indole nucleus of melatonin is not essential 
for its biological activity. First, it was shown that the benzo[b]th~ophene analogue of 
melatonin, N-acetyl-5-methoxy-3-(2-aminoethyl)benzo[b]thiophene (41), possesses the 
ability to induce pigment aggregation in single cultured Xenopus laevzs melanophores, 
although this compound is less potent than melatonin itself [153]. Interestingly, in the 
same SAR study a comparison of methoxy substitution at different positions of the 
benzo[b]thiophene nucleus showed that the 6-methoxy analogue (42) is inactive, yet the 
4-methoxy analogue (40) retains some activity. A similar potency order for these 
analogues was established in 2-[1251]iodomelatonin competition experiments on 
chicken brain and ovine pars tuberalis membranes [153,160]. Second, it was shown that 
the naphthalene analogue of melatonin, N-[2-(7-methoxy-1-naphthaleny1)ethyllacet- 
amide (43 [S-20098, MNEA]) displays the same ability as melatonin to compete for 2- 
[1251]iodomelatonin binding to ovine pars tuberalis membranes and that of the tested N- 
acyl analogues of this naphthalenic bioisostere of melatonin the ones, possessing a N- 
propionyl(44), N-butyryl(45), N-valeroyl (46) or N-cyclopropanecarbonyl group (47), 
display a higher affinty for the labelled melatonin receptor than the parent compound 
S-20098 (43) [180,181]. The latter observation predicts that the active site of the 
Chart 4.9 Chemical structures of methoxy-substituted N-acetyl-3-(2-aminoethyl)benzo[b]thiophenes 
(40-42) and 2-(7-methoxy- 1 -naphthalenyl)ethylamides (43-47). 
labelled melatonin receptor incorporates a hydrophobic pocket of relatively small size, 
which is important to ligand binding [180]. Additional studies revealed that S-20098 
(43) displaces 2-[1251]iodomelatonin binding from chicken retinal membranes with a 
17-fold higher affinity than melatonin [182], inhibits in vitro the rabbit retinal dopamine 
release with a 17-fold higher potency than melatonin [182], Inhibits equipotent with 
melatonin the forskolin-stimulated CAMP production in the ovine pars tuberalis 118 1, 
1831, prevents in vivo testes growth in Siberian hamsters [182], re-entrains the wheel- 
running activity rhythm of Long Evans rats by phase advancing [183], and entrains the 
free-running rhythms of locomotor activity of Long Evans rats [184]. These results 
demonstrated that S-20098 (43) acts in vitro as well as in vivo as a potent melatonin- 
receptor agonist. 
From the SAR studies executed with melatonin and melatonin analogues it can be 
concluded that the 5-methoxy group and the N-acetyl group are essential structural 
entities of melatonin (1) to elicit its specific biological activity. Structural modifications, 
leading to melatonin analogues, which are (almost) equipotent with melatonin or even 
more potent than melatonin as melatonin-receptor agonists, include the replacement of 
the N-acetyl group by another small-sized N-acyl group -N-formyl is too small- 
(14,15,27,28,38,44-47), the saturation of the C2-C3 bond of the indole nucleus (32,33), 
methyl or halogen substitution at the Zposition of the indole nucleus (29,34-39), 
halogen substitution at the 6-position of the indole nucleus (23,24,27,28,33,34), and the 
bioisosteric replacement of the indole nucleus by a naphthalene nucleus (43-47). 
4.5.3 MELATONIN-RECEPTOR ANTAGONISTS AND PARTIAL AGONISTS 
In 1975 Heward and Hadley, determining the frog skin-lightening activity of 
melatonin and related indoleamines using semiquantitative in vitro photometric 
measurements of reflectance, reported that N-acetyltryptamine (3) possesses the ability 
to block in a competitive way melatonin-induced lightening of MSH-darkened frog 
skins, while it possesses no intrinsic skin-lightening activity in this in vitro functional 
bioassay [157]. This suggests that N-acetyltryptamine (3) is a melatonin-receptor 
antagonist. Mainly based on this observation, they concluded that the N-acetyl group of 
melatonin (1) is primarily responsible for affinity at the melanophoric melatonin 
receptor and the 5-methoxy group of melatonin (1) for intrinsic activity at this receptor. 
In a two years later performed SAR-study, using single cultured Xenopus laevis 
melanophores to measure in vitro the pigment aggregation responses to melatonin and 
some analogues, Messenger and Warner could not confirm the melatonin-receptor 
antagonistic properties of N-acetyltryptamine (3) [151]. In contrast, Dubocovich 
showed that N-acetyltryptamine (3) antagonizes competitively the melatonin-induced 
inhibition of dopamine release from chicken retina, but that it has no direct effect on 
this release when added alone, as expected of a melatonin-receptor antagonist [76,185]. 
However, using rabbit retina instead of chicken retina in this in vitro functional 
bioassay, N-acetyltryptamine (3) appeared to be a melatonin-receptor partial agonist, 
i.e. it inhibits not only directly the dopamine release, although submaxirnally, but also 
antagonizes competitively the melatonin-induced inhibition of this release [76]. 
Chart 4.10 Chemical structures of melatonin (I), N-acyltryptamine (3), and 5-substituted N-acetyl-2- 
benzyltryptamines (48 [luzindole, N-07741, 49 [5-methoxyluzindole, N-07451). 
In search of an antagonist for mammalian melatonin receptors Dubocovich 
prepared, by attachment of a lipophilic benzyl group to the 2-position of the indole 
nucleus of N-acetyltryptamine (3), N-acetyl-2-benzyltryptamine (48), also referred to as 
luzindole or N-0774. Luzindole (48) was shown to be a competitive melatonin-receptor 
antagonist in the rabbit retina dopamine release assay [172]. However, the ability of 
luzindole (48) to compete for 2-[1251]iodomelatonin binding to whole chicken brain 
homogenates, retinal membranes and isolated chicken brain areas was shown to be of 
moderate to low potency [129,186,187]. Additional studies of the group of Dubocovich 
revealed that luzindole (48) also acts in some in vivo assays as a melatonin-receptor 
antagonist. Luzindole (48) probably reduces immobility, thus exerts antidepressant-like 
activity, in the C3HlHeN mouse behavioural despair test by inhibition of the in vivo 
effects of endogenous melatonin [I881 and it antagonizes completely the 6- 
chloromelatonin-induced reduction of noradrenaline depletion elicited by a-methyl-p- 
tyrosine in the C3HlHeN mouse hypothalamus [189]. However, luzindole (48) is unable 
to counteract the testicular regression and loss of body weight, induced by melatonin in 
male Siberian hamsters [190]. The pharmacological properties of luzindole (48) were 
also investigated by other research groups. The results of these investigations agree well 
with each other as far as the displacement of 2-[1251]iodomelatonin binding is 
concerned. Luzindole (48) has only a weak affinity at melatonin receptors in ovine pars 
tuberalis, chicken brain, and chicken retinal membranes [191,192]. However, they 
disagree about the melatonin-receptor antagonistic properties of luzindole (48). Howell 
and Morgan found no evidence that luzindole (48) behaves as a melatonin-receptor 
antagonist as it fails to antagonize the melatonin-induced inhibition of forskolin- 
stimulated CAMP production in primary cultures of ovine pars tuberalis cells [191]. In 
contrast, Sugden demonstrated that luzindole (48) does act as a melatonin-receptor 
antagonist as it antagonizes the pigment-aggregation activity of melatonin in single 
cultured Xenopus laevis melanophores and has no pigment aggregation activity of its 
own [192]. Comparing the results of Dubocovich and Sugden, luzindole (48) appears to 
be a somewhat more potent melatonin-receptor antagonist in rabbit retina than in 
amphibian melanophores [172,192]. Sugden also demonstrated that N-acetyltryptamine 
(3) acts as a partial agonist towards melanophoric melatonin receptors [192]. 
In addition, Dubocovich prepared N-acetyl-2-benzyl-5-methoxmtamine (49), 
also referred to as 5-methoxyluzindole or N-0745. 5-Methoxyluzindole (49) was shown 
to act in vitro as well as in vivo as a melatonin-receptor partial agonist [193]. 
Determination of the potency of 5-methoxyluzindole (49) to compete for 2- 
[1251]iodomelatonin binding to chicken retinal membranes revealed that this compound 
is only slightly less potent than the melatonin-receptor agonist 6-chloromelatonin, but 
much more potent than luzindole (48) and N-acetyltryptamine (3) [129,186]. 
Considering the affmities and intrinsic activities of melatonin (I), a full melatonin- 
receptor agonist of high affinity, N-acetyltryptamine (3), a melatonin-receptor 
antagonist or melatonin-receptor partial agonist of low affinity, luzindole (48), a 
melatonin-receptor antagonist of moderate to low affinity, and 5-methoxyluzindole (49), 
a melatonin-receptor partial agonist of high affinity, in relation to their chemical 
structures, it can be concluded that the 5-methoxy group of indolic melatonin-receptor 
agents is not only important for their intrinsic activities at melatonin receptors, but also 
for their affinities at these receptors. In addition, it can be concluded that a benzyl 
substituent at the 2-position of indolic melatonin-receptor agents almost does not affect 
their affinities for melatonin receptors. However, this substituent lowers the intrinsic 
activities of melatonin-receptor agents. 
Some years ago, Zisapel and Laudon introduced another putative melatonin- 
receptor antagonist, namely N-(2,4-dinitrophenyl)-5-methoxybyptamine (50), also 
referred to as ML-23 [194]. Markedly, this compound lacks an amido group as a 
functional moiety. They showed that ML-23 (50) antagonizes in vitro the melatonin- 
induced inhibition of dopamine release from female rat hypothalamus [194], and 
counteracts in vivo the melatonin-induced delay of sexual maturation of young male as 
well as young female rats [194,195] and the melatonin-induced inhibition of ovulation 
Chart 4.11 Chemical structure of N-(2,4-dinitriphenyl)-5-methoxytryptamine (50 [ML-231). 
in mature female rats [195]. However, several other research groups were unable to 
show that ML-23 (50) acts in vitro or in vivo as a melatonin-receptor antagonist 
[172,192,196-1981. 
In conclusion, it can be said that at this moment luzindole (48) is the best 
competitive melatonin-receptor antagonist available. However, the search for melatonin- 
receptor antagonists of high affinity, which antagonize in vitro as well as in vivo most 
of the effects induced by melatonin, must go on in order to understand better the mode 
of action of melatonin. 
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